Cullinan Therapeutics heads into its September 14 earnings report with short sellers firmly in place and options traders tilting defensive — despite a stock that has recovered sharply over the past month.
Short interest is the defining feature of this setup. At roughly 17.8% of the free float, it is a genuinely elevated position for a clinical-stage biotech — nearly 10.5 million shares short, and that figure has crept up about 3.7% over the past month. Despite a small daily dip on September 9, the short position has barely budged over the past week. Days to cover stand at over 15 sessions, meaning any forced unwind would take time. Notably though, the borrow market is not under stress: availability runs at around 521% — more than five shares available to lend for every one already borrowed — and cost to borrow remains modest at 0.56%. This is a well-established short, not a fresh squeeze setup. Borrow is cheap and plentiful. The bears are comfortable.
Options positioning has turned more defensive into the print. The put/call ratio closed at 1.196 on September 10 — above its 20-day average of 1.09 and close to the 52-week high of 1.25. The PCR has been running elevated for the past two weeks, a sustained rather than single-day spike. That coincides with a stock that fell 5.2% over the past week to $21.00, after a strong 14.9% month. Together, recent price weakness and hedging demand paint a picture of investors protecting gains rather than pressing new long positions ahead of the release.
The analyst community is broadly constructive but the stock trades at a steep discount to consensus targets. Wedbush raised its price target to $42 on August 13 — the most aggressive on the street. BTIG holds at $39. The mean target sits near $32, implying roughly 54% upside from current levels. Bulls point to the pipeline depth: CLN-978 in autoimmune, velinotamig in plasma cell disorders, and early clinical data that analysts see as validating multiple mechanisms of action. Bears flag the absence of near-term revenue and the commercial uncertainty around zipalertinib, whose PDUFA was pushed to 2027. Institutional ownership is meaningful — T. Rowe Price added nearly 1.8 million shares last quarter, and State Street crossed the 6% threshold in August — suggesting some large holders are leaning into the story. Insider activity, by contrast, has been one-directional: the CSO sold shares three separate times between May and September, all under a pre-arranged 10b5-1 plan, netting roughly $923,000 in open-market sales over 90 days.
Historical earnings reactions add an interesting wrinkle. The last four prints have all delivered positive one-day moves, ranging from 0.7% to 11%. The five-day drifts have been stronger still, with two of the last four events producing five-day gains above 11%. The print on September 14 will test whether the pipeline progress bulls have been pricing in can withstand scrutiny — and whether short sellers sitting on a crowded but comfortable position have reason to cover or to add.
See the live data behind this article on ORTEX.
Open CGEM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
